ClinicalTrials.gg
TerminatedNCT00765323Updated Sep 27, 2013

Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly

A Phase 3 interventional study of Octreotide Implant and Sandostatin LAR Depot in Acromegaly, sponsored by Endo Pharmaceuticals. Terminated at 47 sites in 9 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2013-09-27.

Sponsored by Endo Pharmaceuticals (part of Keenova Therapeutics plc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
169
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing octreotide in Acromegaly — 1 open to participants now, 1 under way, 1 of them phase 3. Octreotide · Acromegaly.

Enrollment
Largest of 25
169 · median 56
Started
2008
with 1 other
Phase 3
12 of 25
1 open now
Registered
12th of 25
by date
Lead sponsor
3 of 25
Endo Pharmaceuticals

Among the 25 studies testing octreotide in Acromegaly, this one has the largest enrollment, is one of 2 that started in 2008, is one of 12 in phase 3, and was the 12th registered.

Acromegaly

202 studies on the registry are indexed under Acromegaly; 19 are open to participants now.

Browse Acromegaly studies →

Open to participants now

1 of the 25 studies testing octreotide in Acromegaly is open now. Recruiting first, the newest first:

About octreotide

Octreotide: first FDA approval 1988 (SANDOSTATIN), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Acromegaly studies recruiting now, 7 (50%) set no upper age limit and 5 (36%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing octreotide in Acromegaly, or all of them as a file.
02

Study summary

Evaluate the efficacy, safety and tolerability of the octreotide implant in patients with acromegaly that were previously treated with octreotide depot.

Read the detailed description

This study will be conducted in 3 phases: Screening, the Primary Treatment Phase (ie, Day 1 to Week 24), and the Extension Phase (Post Week 24 to Week 48). Primary efficacy and safety will be determined from the Primary Treatment Phase. Eligible patients will be randomized during the Primary Treatment Phase; in a 3 to 1 ratio to receive 6 months of open-label treatment with either the 84 mg octreotide implant or monthy Injections of S-LAR. Each patient in this study will return to the investigational center every 4 weeks; safety and efficacy assessments will be performed during these visits. All patients who complete the Primary Treatment Phase and who continue to meet eligibility criteria will be offered the opportunity to enter the Extension Phase; patients entering the Extension Phase will be treated with an octreotide implant for 6 months.During the Extension Phase, patients will return to the investigational center every 4 weeks; safety and efficacy assessments will be performed during these visits.

03

Conditions studied

  • Acromegaly

Browse trials for

Keywords

  • Octreotide
  • Sandostatin LAR
  • Growth hormone
  • IGF-1
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients with acromegaly
  • Confirmed diagnosis of a growth hormone-secreting tumor
  • Received a stable dose of monthly octreotide depot injections for a minimum of 3 consecutive months immediately prior to screening
  • Must show a response to octreotide treatment with documented laboratory results at the screening visits defined as follows: IGF-1 \< 20% above the age and sex-adjusted levels and GH ≤ 2.5 ng/mL

Exclusion criteria

Exclusion Criteria:

  • Patients with pituitary surgery less than 3 months prior to screening
  • Uncontrolled diabetes defined as having a fasting glucose > 150 mg/dl and >= 9%
  • Symptomatic cholelithiasis
  • Received pegvisomant, Lanreotide, or a dopamine agonist within 3 months of screening, or at any time during the trial
  • Received radiotherapy for pituitary tumor or any radiotherapy above the neck at any time before Screening
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
169 participants (actual)

Study arms

  • Active comparator
    1

    84 mg octreotide implant for 6 months

    Drug: Octreotide Implant

  • Active comparator
    2

    Injections of Sandostatin LAR Depot(20, 30, 40 mg) every 4 weeks

    Drug: Sandostatin LAR Depot

Interventions

  • 84 mg octreotide subcutaneous implant for 6 months

    Also known as: somatostatin analogue

  • Injections of Sandostatin LAR (dose range \~10-40 mg every 28 days)

    Also known as: somatostatin analogue

06

What researchers measure

Primary outcomes

  1. Efficacy based on IGF-1, GH, signs and symptoms scores, tumor size, QoL and Patient Treatment Assessments

    Time frame: 12 months

07

Study locations

47 sites
  • Stanford University Medical Center - Stanford Hospitals and Clinics
    Palo Alto, California 94304, United States
  • University of Colorado - Veterans Administration Medical Center - Endocrinology
    Denver, Colorado 80220, United States
  • Galiz Research
    Miami, Florida 33145, United States
  • The University of Illinois at Chicago
    Chicago, Illinois 60608, United States
  • Sinai Hospital of Baltimore, Medicine - Div. of Endocrinology and Metabolism
    Baltimore, Maryland 21215, United States
  • The Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Oregon Health and Science University, Endocrinology
    Portland, Oregon 97239, United States
  • Seattle Neuroscience Institute - Swedish Medical Center
    Seattle, Washington 98122, United States
  • 2. interni klinika fakultní nemocnice Hradec Králové
    Hradec Kralove, Czech Republic
  • 3. interni klinika Vseobecne fakultni nemocnice
    Prague, Czech Republic
  • Charité Berlin, Campus Benjamin Franklin, Abteilung fϋr Endokrinologie, Diabetes und Ernährungsmedizin
    Berlin, Germany
  • Universitätsklinikum Erlangen, Medizinische Klinik 1, Gastroenterologie, Pneumologie und Endokrinologie
    Erlangen, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität, Medizinische Klinik 1, Endokrinologie
    Frankfurt, Germany
  • Universitätsklinikum Hamburg-Eppendorf - Bereich Endokrinologie, Diabetologie und Adipositas
    Hamburg, Germany
  • Universitätsklinikum zu Köln, Klinik und Poliklinik II Innnere
    Koln, Germany
  • Universitätsklinikum Schleswig-Holstein, Medizinische Klinik 1
    Lubeck, Germany
  • Klinik für Endokrinologie und Stoffwechselkrankheiten Otto-von-Guericke-Universität Magdeburg
    Magdeburg, Germany
  • Klinikum der Philipps Universitaet Marburg Bereich Endokrinologie & Diabetologie
    Marburg, Germany
  • Semmelweis University, Faculty of Medicine, 2nd Department of Medicine
    Budapest, Hungary
  • University of Debrecen Medical and Health Science Center, Division of Endocrinology
    Debrecen, Hungary
  • University of Pécs, School of Medicine, 1st Department of Medicine
    Pecs, Hungary
  • Akademickie Centrum Kliniczne - Szpital Akademii Medycznej w Gdańsku
    Gdańsk, Poland
  • Szpital Kliniczny im. Heliodora Święcickiego Uniwersytetu Medycznego im. Karola Marcinkowskiego w Poznaniu
    Poznań, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska Dr n. med. Grzegorz Kulig
    Szczecin, Poland
  • Szpital Bielański im. Ks. Jerzego Popiełuszki SPZOZ
    Warsaw, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr 1 we Wrocławiu, Klinika Endokrynologii, Diabetologii i Leczenia Izotopami
    Wroclaw, Poland
  • State Institution of Healthcare "Regional Clinical Hospital"
    Barnaul, Russian Federation
  • State Intitution of Healthcare "Mark of Honour "Irkutsk Regional Clinical Hospital"
    Irkutsk, Russian Federation
  • State Institution of Healthcare "Kemerovo State Clinical Hospital"
    Kemerovo, Russian Federation
  • Regional State Institution of Healthcare "Regional State Hospital"
    Krasnoyarsk, Russian Federation
  • Federal State Institution "Endocrinology Research Center of Rosmedtechnology"
    Moscow, Russian Federation
  • State Educational Institution of High Professional Education "Moscow Medical Academy named after I.M. Sechenov of Federal Agency of Healthcare and Social Development"
    Moscow, Russian Federation
  • State Institution Moscow Regional Scientific-Research Clinical Institute named after M.F. Vladimirsky
    Moscow, Russian Federation
  • State Institution of Healthcare "N. Novgorod Regional Clinical Hospital named after N.A. Semashko"
    Nizhniy Novgorod, Russian Federation
  • State Educational Institution of High Professional Education "Novosibirsk State medical Univeristy of Federal Agency of Healthcare and Social Development
    Novosibirsk, Russian Federation
  • State Educational Institution of High Professional Education "Perm State Medical Academy named after academician E.A.Vagner of Roszdrav"
    Perm, Russian Federation
  • Center "Diabetes", LLC
    Samara, Russian Federation
  • Federal State Institution "federal Center of Heart, Blood and Endocrinology named after V.A. Almazov of Rosmedtechnology"
    St. Petersburg, Russian Federation
  • National Educational Institution of Additional Professional Education "St. Petersburg Medical Academy of Postgraduate Studies of Roszdrav"
    St. Petersburg, Russian Federation
  • State Educational Institution of High Professional Education "Siberian State Medical University of Federal Agency of Healthcare and Social Development"
    Tomsk, Russian Federation
  • Municipal Health Care Institution Clinical Hospital for Emergency Medical Care named after N.V. Solovyov
    Yaroslavl, Russian Federation
  • Institute of Endocrinology
    Belgrade, Serbia
  • Endotopmed s.r.o., Tehelná
    Bratislava, Slovakia
  • Národný endokrinologický a diabetologický ústav
    Lubocna, Slovakia
  • Hospital General Universitario de Alicante Endocrinología y Nutrición
    Alicante, Spain
  • Hospital Universitario Gregorio Marañón Endocrinología y Nutrición
    Madrid, Spain
  • Hospital Universitario la Fé Endocrinología y Nutrición
    Valencia, Spain
08

References and documents

Publications

  • Chieffo C, Cook D, Xiang Q, Frohman LA. Efficacy and safety of an octreotide implant in the treatment of patients with acromegaly. J Clin Endocrinol Metab. 2013 Oct;98(10):4047-54. doi: 10.1210/jc.2013-2262. Epub 2013 Aug 22. PubMed 23969184 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2008, a primary completion of Feb 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2008
First posted
Oct 2, 2008
Start
Sep 2008
Primary completionActual
Feb 2011
CompletionActual
Jun 2011
Results delay requested
Mar 5, 2012
Last update
Sep 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00765323
Responsible party
Sponsor
First posted
Oct 2, 2008
Start date
Sep 2008
Primary completion
Feb 2011
Completion
Jun 2011
Last update
Sep 27, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Octreotide

Start the discussion